Nearly 4% of the world’s population is affected by one of more than 80 different autoimmune diseases, according to the National Stem Cell Foundation, and incidence is rising.
However, of the 30 million patients diagnosed with moderate-to-severe forms of chronic immune diseases, only 5 million receive advanced therapies and only 2 million experience adequate responses.[1] A key barrier to the development of novel therapies and treatment paradigms has been the complexity and heterogeneity of these diseases, which consist of different disease states with distinct unmet medical need and biology.